- AU$12.30m
- AU$11.33m
- AU$0.64m
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology
Australia's Cambium Bio hits 7-week high on premium placement
Brief: Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate Ocular
Australia's Cambium Bio advances on signing MoU for Elate Ocular
Brief: Cambium Bio Signs $2.0M Licensing Deal For Fibrin Biologic In Dental Applications
Australia's Cambium Bio rises on premium placement
Brief: Cambium Bio To Raise A$2.12 Million Through Placement
Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug
Brief: Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate Ocular
Brief: Cambium Bio Says Chair Barry Sechos Retires
Brief: Cambium Bio Says FDA Approves Potency Assay Strategy
Brief: Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
Brief: Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular
Brief: Cambium Bio Requests Trading Halt Due To Proposed Capital Raising
Brief: Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co
Australia's Cambium Bio eyes best day ever on completion of merger